Previous researches have shown that the combination of Tim-3+ blockade with PD-1+ pathway blockade was remarkably more effective in colon carcinoma, acute myelogenous leukemia, and melanoma models than with blockade of either the Tim-3+ or PD-1+ pathway alone [41, 42]. The gene discussed is HAVCR2; the disease is colon carcinoma.